Key terms
About ARGX
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ARGX news
May 17
1:55pm ET
Jefferies biotech analyst holds an analyst/industry conference call
May 17
12:08pm ET
Jefferies biotech analyst holds an analyst/industry conference call
May 17
12:08pm ET
Jefferies biotech analyst holds an analyst/industry conference call
May 15
5:38am ET
Argenx SE: Strong Buy Rating on Vyvgart’s Market Expansion and Promising Pipeline
May 14
7:10am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
May 13
3:03pm ET
Argenx price target lowered to EUR 470 from EUR 490 at JPMorgan
May 13
11:30am ET
Analysts Conflicted on These Healthcare Names: Guardant Health (GH), Argenx Se (ARGX) and Annexon Biosciences (ANNX)
May 13
7:10am ET
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), ANI Pharmaceuticals (ANIP) and Argenx Se (ARGX)
May 12
10:07pm ET
Stifel Nicolaus Keeps Their Buy Rating on Argenx Se (ARGX)
May 10
8:40am ET
Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Plus Therapeutics (PSTV) and Argenx Se (ARGX)
May 10
8:02am ET
Oppenheimer Reaffirms Their Hold Rating on Argenx Se (ARGX)
May 10
6:27am ET
Buy Rating Affirmed for Argenx Se: Strong Vyvgart Launch and Promising Global Expansion Outlook
May 10
5:53am ET
Argenx price target lowered to $468 from $471 at JMP Securities
May 10
5:18am ET
Buy Rating on Argenx Se Backed by Vyvgart’s Strong Sales and Market Expansion Potential
May 10
5:06am ET
Buy Rating Affirmed for Argenx Amid Strong Vyvgart Launch and Promising Commercial Prospects
May 10
4:30am ET
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT) and Argenx Se (ARGX)
May 10
1:33am ET
Buy Rating on Argenx Se Backed by Strong Vyvgart Sales and Expanding Pipeline
May 10
12:56am ET
Buy Rating for Argenx Se Backed by Strong VYVGART Sales and Promising Pipeline Prospects
May 09
7:58am ET
Argenx Q1 2024: Strong Sales and Pipeline Progress
May 09
5:39am ET
Argenx reports Q1 EPS ($1.04), consensus (76c)
Apr 30
6:53am ET
Biotech Sector: M&A Fuels Renewed Excitement
Apr 26
7:50am ET
Piper Sandler Sticks to Its Buy Rating for Argenx Se (ARGX)
Apr 19
5:50am ET
Analysts’ Top Healthcare Picks: Elevance Health (ELV), Argenx Se (ARGX)
Apr 18
12:25pm ET
Maintaining the Edge: Argenx’s Hold Rating Amidst Rising Competition and Promising Therapy Results
Apr 18
6:30am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)
Apr 16
6:58am ET
Argenx’s VYVGART Shows Promising CIDP Treatment Results
Apr 16
5:33am ET
Argenx presents data from ADHERE trial evaluating Vyvgart Hytrulo
Apr 15
7:10am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)
Apr 12
9:36am ET
Argenx Se (ARGX) Receives a Buy from Bank of America Securities
Apr 03
4:15am ET
UBS Reaffirms Their Hold Rating on Argenx Se (ARGX)
Mar 29
3:09am ET
Buy Rating Affirmed for Argenx Se on Efgartigimod Progress and Regulatory Success
No recent press releases are available for ARGX
ARGX Financials
Key terms
Ad Feedback
ARGX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ARGX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
